

2022 IMPACT REPORT

Accelerating life-transforming therapies for Phelan-McDermid syndrome

Promoting Patient-Focused Drug Development

Externally-Led
Patient-Focused
Drug Development



EL-PFDD meeting for PMS

before the FDA


\$80,000

- held in November 2022
- nearly 300 families participated
- more than 150 written comments
- attended by 13 Companies

30 Researchers &

16 FDA Regulators

Phelan-McDermid syndrome **CONCEPTUAL MODEL**



\$25,000

- data extracted from 15 peerreviewed publications
- 96 disease signs and symptoms
- represented 13 observerreportable patient impacts
- 31 caregiver impacts

Created two new REAL FAMILY STORIES videos



\$10,000

- self-injurious behaviors
- severe hypotonia

Accelerating Translation of Research to Therapeutics

CureSHANK

e e e

Biomarkers and OutcomeMeasures Consortium \$100,000



Retained a project manager and legal team Engaged with 22 potential industry partners Developed governance and terms of participation

PMS Community Engagement

Two Community Webinars updating & engaging the PMS community on CureSHANK's work

